| Literature DB >> 34885460 |
Ayumi Nanri1,2, Masaaki Yoshida1,3, Yoshiyuki Ishida2, Daisuke Nakata2, Keiji Terao2, Florencio Jr Arce4,5, Gerard Lee See4,5, Takashi Tanikawa3, Yutaka Inoue1,3.
Abstract
Cyclodextrin-based metal-organic frameworks-1 (CD-MOF-1) prepared using potassium hydroxide, ethanol, and γ-cyclodextrin (γ-CD) has been reported as a new type of MOF for the development of pharmaceutical formulations. The present study aimed to investigate the physicochemical properties of ascorbic acid derivatives (L-ascorbyl 6-palmitate (ASCP); L-ascorbyl 2,6-palmitate (ASCDP)) complexed with CD-MOF-1 by a solvent evaporation method. Powder X-ray diffraction revealed that the crystal diffraction pattern of CD-MOF-1 changed from α-type to β-type when prepared by a solvent evaporation method. For ASCP/CD-MOF-1 = 1/2 and ASCDP/CD-MOF-1 = 1/4 evaporated samples, the crystal diffraction peaks derived from ASCP and ASCDP disappeared, indicating a β-like behavior. Differential scanning calorimetry results revealed that the endothermic peaks of evaporated samples (ASCP/CD-MOF-1 = 1/2 and ASCDP/CD-MOF-1 = 1/4) were not detected due to melting. Furthermore, intermolecular interactions were observed in the hydrogen bonds between the CH groups of the side chains of ASCP and ASCDP and the OH group of CD-MOF-1 in (ASCP/CD-MOF-1 = 1/2) and EVP (ASCDP/CD-MOF-1 = 1/4), based on the near-infrared absorption spectroscopy analysis. CD-MOF-1 did not form inclusion complexes with the lactone rings of ASCP and ASCDP, but with the lipophilic side chains. These results suggested that CD-MOF-1 may be useful in preparing novel drug carriers for ASCP and ASCDP.Entities:
Keywords: MOF-1; ascorbic acid; cyclodextrin; drug carrier; inclusion complex
Year: 2021 PMID: 34885460 PMCID: PMC8658738 DOI: 10.3390/ma14237309
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.623
Figure 1Chemical structures of: (a) CD-MOF-1; (b) γ-CD; (c) ASC; (d) ASCP; (e) ASCDP; (f) γ-CD(KOH)2.
Figure 2PXRD patterns of: (a) γ-CD; (b) CD-MOF-1; (c) EVP (CD-MOF-1); (d) ASCP intact; (e) PM (ASCP/CD-MOF-1 = 1/1); (f) EVP (ASCP/CD-MOF-1 = 1/1); (g) EVP (ASCP/CD-MOF-1 = 1/2); (h) ASCDP intact; (i) PM (ASDCP/CD-MOF-1 = 1/1); (j) EVP (ASCDP/CD-MOF-1 = 1/1); (k) EVP (ASCDP/CD-MOF-1 = 1/2); (l) EVP (ASCDP/CD-MOF-1 = 1/4). ●: γ-CD original, ■: CD-MOF-1 original (α type), □: CD-MOF-1 original (β type), ▲: ASCP original, △: ASCDP original.
Figure 3DSC curves of: (a) γ-CD; (b) CD-MOF-1; (c) EVP (CD-MOF-1); (d) ASCP intact; (e) PM (ASCP/CD-MOF-1 = 1/1); (f) EVP (ASCP/CD-MOF-1 = 1/1); (g) EVP (ASCP/CD-MOF-1 = 1/2); (h) ASCDP intact; (i) PM (ASDCP/CD-MOF-1 = 1/1); (j) EVP (ASCDP/CD-MOF-1 = 1/1); (k) EVP (ASCDP/CD-MOF-1 = 1/2); (l) EVP (ASCDP/CD-MOF-1 = 1/4).
Figure 4(A) Second differentiation NIR absorption spectra of ASCP/CD-MOF-1 systems: (1) 8800–8000 cm−1; (2) 7500–6700 cm−1; (3) 6000–4500 cm−1. (B) Second differentiation NIR absorption spectra of ASCDP/CD-MOF-1 systems: (1) 8800–8000 cm−1; (2) 7500–6700 cm−1; (3) 6000–4500 cm−1.
Figure 5(A) SEM micrographs of: (a) γ-CD; (b) CD-MOF-1; (c) EVP (CD-MOF-1); (d) ASCP intact; (e) PM (ASCP/CD-MOF-1 = 1/2); (f) EVP (ASCP/CD-MOF-1 = 1/1); (g) EVP (ASCP/CD-MOF-1 = 1/2). (B) SEM micrographs of: (h) ASCDP intact; (i) PM (ASCDP/CD-MOF-1 = 1/4); (j) EVP (ASCDP/CD-MOF-1 = 1/1); (k) EVP (ASCDP/CD-MOF-1 = 1/2); (l) EVP (ASCDP/CD-MOF-1 = 1/4).
Figure 6(A) 1H-1H NOESY NMR spectra EVP (ASCP/CD-MOF-1 = 1/2) in D2O: (1) f1 is 3.0–4.0 ppm, f2 is 0.0–10.0 ppm; (2) f1 is 3.0–4.0 ppm, f2 is 3.5–5.5 ppm; (3) f1 is 3.0–4.0 ppm, f2 is 0.5–2.5 ppm. (B) 1H-1H NOESY NMR spectra EVP (ASCDP/CD-MOF-1 = 1/4) in D2O: (1) f1 is 3.0–4.0 ppm, f2 is 0.0–10.0 ppm; (2) f1 is 3.0–4.0 ppm, f2 is 4.0–5.5 ppm; (3) f1 is 3.0–4.0 ppm, f2 is 0.5–2.5 ppm.
Scheme 1Structural view of ASCP/CD-MOF-1 complex.
Scheme 2Structural view of ASCDP/CD-MOF-1 complex.